Scynexis Q1 net loss widens on higher R&D costs

Scynexis

11/05/2026 21:35

Overview

U.S. biotech firm's Q1 net loss widened on higher R&D tied to SCY-770 acquisition

Company completed $37.2 mln private placement, extending cash runway to mid-2029

Result Drivers

SCY-770 ACQUISITION COSTS - Higher R&D expenses were mainly driven by an $8 mln IPR&D expense for the acquisition of SCY-770

WARRANT LIABILITY ADJUSTMENT - Higher other expenses reflected a $5.2 mln loss from fair value adjustment of warrant liabilities due to stock price increase

PRIVATE PLACEMENT COSTS - SG&A expenses rose due to a $0.8 mln write-off of offering costs for the March 2026 private placement warrant issuance

Company press release: ID:nGNX7ycQTW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$21.30 mln
Q1 Basic EPS
-$0.42
Q1 Operating Expenses
$16.94 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for SCYNEXIS Inc is $4.00, about 336.8% above its May 8 closing price of $0.92

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)